Soleno Therapeutics, Inc.
NASDAQ: SLNO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anish Bhatnagar
- Employees
- 115
- Headquarters
- Redwood City, United States
- IPO year
- 2014
- Market cap
- $2.8B
- Website
- https://soleno.life
Loading SLNO…
Loading profile data…Frequently asked questions about SLNO
What does Soleno Therapeutics, Inc. (SLNO) do?
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome,...
Where does SLNO trade?
Soleno Therapeutics, Inc. (SLNO) trades on the NASDAQ Capital Market.
What sector is SLNO in?
Soleno Therapeutics, Inc. (SLNO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Soleno Therapeutics, Inc.?
Anish Bhatnagar is the chief executive officer of Soleno Therapeutics, Inc. (SLNO).
Where is Soleno Therapeutics, Inc. headquartered?
Soleno Therapeutics, Inc. is headquartered in United States.
Does SLNO pay a dividend?
Soleno Therapeutics, Inc. (SLNO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLNO go public?
Soleno Therapeutics, Inc. (SLNO) completed its initial public offering in 2014.